Predictive value of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) combined with D-dimer for no-reflow phenomenon in patients with acute coronary syndrome after emergency of percutaneous coronary intervention

References

• Makki N, Brennan TM, Girotra S. Acute coronary syndrome. J Intensive Care Med. 2015 May;30(4):186–200.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017 Nov 1;38(41):3070–3078.
   PubMed Web of Science ®Google Scholar
• Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation. 2003 Oct 14;108(15):1772–1778.
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013 Jan 1;127(1):143–152.
   PubMed Web of Science ®Google Scholar
• Lassen JF, Burzotta F, Banning AP, et al. Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. EuroIntervention. 2018 Jan 20;13(13):1540–1553.
   PubMed Web of Science ®Google Scholar
• Ayca B, Akin F, Celik O, et al. Neutrophil to lymphocyte ratio is related to stent thrombosis and high mortality in patients with acute myocardial infarction. Angiology. 2015 Jul;66(6):545–552.
   PubMed Web of Science ®Google Scholar
• Nunez J, Nunez E, Bodi V, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol. 2008 Mar 15;101(6):747–752.
   PubMed Web of Science ®Google Scholar
• Zhou SS, Tian F, Chen YD, et al. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction. J Geriatr Cardiol. 2015 Mar;12(2):135–142.
   PubMedGoogle Scholar
• Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003 Jan;145(1):42–46.
   PubMed Web of Science ®Google Scholar
• Toprak C, Tabakci MM, Simsek Z, et al. Platelet/lymphocyte ratio was associated with impaired myocardial perfusion and both in-hospital and long-term adverse outcome in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Postepy Kardiol Interwencyjnej. 2015;11(4):288–297.
   PubMed Web of Science ®Google Scholar
• James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003 Jul 22;108(3):275–281.
   PubMed Web of Science ®Google Scholar
• Hong SN, Ahn Y, Hwang SH, et al. Usefulness of preprocedural N-terminal pro-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol. 2007 Aug 15;100(4):631–634.
   PubMed Web of Science ®Google Scholar
• Huang D, Gao W, Wu R, et al. D-dimer level predicts in-hospital adverse outcomes after primary PCI for ST-segment elevation myocardial infarction. Int J Cardiol. 2020 Apr 15;305:1–4.
   PubMed Web of Science ®Google Scholar
• Akgul O, Uyarel H, Pusuroglu H, et al. Predictive value of elevated D-dimer in patients undergoing primary angioplasty for ST elevation myocardial infarction. Blood Coagul Fibrinolysis. 2013 Oct;24(7):704–710.
   PubMed Web of Science ®Google Scholar
• Erkol A, Oduncu V, Turan B, et al. The value of plasma D-dimer level on admission in predicting no-reflow after primary percutaneous coronary intervention and long-term prognosis in patients with acute ST segment elevation myocardial infarction. J Thromb Thrombolysis. 2014 Oct;38(3):339–347.
   PubMed Web of Science ®Google Scholar
• Kim SH, Cho JH, Lee YH, et al. Improvement in left ventricular function with intracoronary mesenchymal stem cell therapy in a patient with anterior wall ST-segment elevation myocardial infarction. Cardiovasc Drugs Ther. 2018 Aug;32(4):329–338.
   PubMed Web of Science ®Google Scholar
• Alpsoy S, Erselcan K, Akyuz A, et al. Can the development of atrial fibrillation in patients with ischemic heart failure with low ejection fraction be predicted? North Clin Istanb. 2020;7(1):18–24.
   PubMed Web of Science ®Google Scholar
• Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016 Jul-Aug;68(4):539–551.
   PubMedGoogle Scholar
• Wong DT, Puri R, Richardson JD, et al. Myocardial ‘no-reflow’–diagnosis, pathophysiology and treatment. Int J Cardiol. 2013 Sep 1;167(5):1798–1806.
   PubMed Web of Science ®Google Scholar
• Fajar JK, Heriansyah T, Rohman MS. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: a meta-analysis. Indian Heart J. 2018 Dec;70(Suppl 3):S406–S418.
   PubMedGoogle Scholar
• Liang T, Liu M, Wu C, et al. Risk factors for no-reflow phenomenon after percutaneous coronary intervention in patients with acute coronary syndrome. Rev Invest Clin. 2017 May-Jun;69(3):139–145.
   PubMedGoogle Scholar
• Yang J, Li CS. [The predictive values of D-dimer for the early prognosis of the acute myocardial infarction (AMI): a review of 3134 AMI patients]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012 Dec;24(12):725–729.
   PubMedGoogle Scholar
• Grabowski M, Filipiak KJ, Karpinski G, et al. Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am Heart J. 2004 Oct;148(4):655–662.
   PubMed Web of Science ®Google Scholar
• Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002 Feb 15;89(4):463–465.
   PubMed Web of Science ®Google Scholar
• Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004 Nov 16;110(20):3206–3212.
   PubMed Web of Science ®Google Scholar
• Goldin Y, Pasvolsky O, Rogowski O, et al. The diagnostic yield of D-Dimer in relation to time from symptom onset in patients evaluated for venous thromboembolism in the emergency medicine department. J Thromb Thrombolysis. 2011 Jan;31(1):1–5.
   PubMed Web of Science ®Google Scholar
• Gorog DA. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol. 2010 Jun 15;55(24):2701–2709.
   PubMed Web of Science ®Google Scholar
• Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J. 2014 Mar;35(9):552–556.
   PubMed Web of Science ®Google Scholar
• Gao R, Wang J, Zhang S, et al. The value of combining plasma D-dimer and endothelin-1 levels to predict no-reflow after percutaneous coronary intervention of ST-segment elevation in acute myocardial infarction patients with a type 2 diabetes mellitus history. Med Sci Monit. 2018 May 28;24:3549–3556.
   PubMed Web of Science ®Google Scholar